CN110914307A - 改进的双特异性多肽分子 - Google Patents

改进的双特异性多肽分子 Download PDF

Info

Publication number
CN110914307A
CN110914307A CN201880046721.2A CN201880046721A CN110914307A CN 110914307 A CN110914307 A CN 110914307A CN 201880046721 A CN201880046721 A CN 201880046721A CN 110914307 A CN110914307 A CN 110914307A
Authority
CN
China
Prior art keywords
ser
val
gly
leu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880046721.2A
Other languages
English (en)
Chinese (zh)
Inventor
M·霍夫曼
F·翁弗多尔本
S·邦克
D·莫勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017115966.5A external-priority patent/DE102017115966A1/de
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Publication of CN110914307A publication Critical patent/CN110914307A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880046721.2A 2017-07-14 2018-07-13 改进的双特异性多肽分子 Pending CN110914307A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762532713P 2017-07-14 2017-07-14
US62/532,713 2017-07-14
DE102017115966.5A DE102017115966A1 (de) 2017-07-14 2017-07-14 Polypeptidmolekül mit verbesserter zweifacher Spezifität
DE102017115966.5 2017-07-14
DE102017119866.0 2017-08-30
DE102017119866 2017-08-30
US201862658318P 2018-04-16 2018-04-16
US62/658,318 2018-04-16
DE102018108995.3 2018-04-16
DE102018108995 2018-04-16
PCT/EP2018/069151 WO2019012138A1 (en) 2017-07-14 2018-07-13 POLYPEPTIDE MOLECULE WITH IMPROVED DOUBLE-SPECIFICITY

Publications (1)

Publication Number Publication Date
CN110914307A true CN110914307A (zh) 2020-03-24

Family

ID=62951983

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880046721.2A Pending CN110914307A (zh) 2017-07-14 2018-07-13 改进的双特异性多肽分子
CN201880046726.5A Pending CN110914308A (zh) 2017-07-14 2018-07-13 改进的双特异性多肽分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880046726.5A Pending CN110914308A (zh) 2017-07-14 2018-07-13 改进的双特异性多肽分子

Country Status (28)

Country Link
US (8) US20190016803A1 (https=)
EP (3) EP3428194B1 (https=)
JP (4) JP2020530762A (https=)
KR (2) KR20200026995A (https=)
CN (2) CN110914307A (https=)
AU (2) AU2018298881B2 (https=)
BR (2) BR112020000769A2 (https=)
CA (2) CA3069842A1 (https=)
CO (2) CO2020001029A2 (https=)
CR (2) CR20200014A (https=)
CY (2) CY1124091T1 (https=)
DK (2) DK3428194T3 (https=)
ES (2) ES2871146T3 (https=)
HR (1) HRP20211744T1 (https=)
HU (2) HUE057110T2 (https=)
LT (2) LT3428194T (https=)
MA (1) MA46299B1 (https=)
MD (2) MD3428194T2 (https=)
MX (1) MX2020011744A (https=)
PE (2) PE20200615A1 (https=)
PL (2) PL3428194T3 (https=)
PT (2) PT3428194T (https=)
RS (2) RS61817B1 (https=)
SG (2) SG11202000025SA (https=)
SI (2) SI3428194T1 (https=)
TW (2) TWI762677B (https=)
WO (2) WO2019012141A1 (https=)
ZA (1) ZA202000842B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021173560A1 (en) 2020-02-24 2021-09-02 Immatics US, Inc. Methods for expanding t cells for the treatment of cancer and related malignancies
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
MX2020012124A (es) 2018-05-14 2021-04-19 Immunocore Ltd Polipeptidos de unión bifuncional.
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy
US20210032370A1 (en) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
CN112409474B (zh) * 2019-08-23 2023-02-28 香雪生命科学技术（广东）有限公司 一种识别ssx2抗原的高亲和力tcr
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
JP7738914B2 (ja) * 2019-12-05 2025-09-16 アーベル リミテッド ＴｒｉＡｘ抗体の組成、その製造方法及び使用方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
GB202006629D0 (en) 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
KR20230135589A (ko) 2020-12-31 2023-09-25 이매틱스 유에스 인코포레이티드 Cd8 폴리펩타이드, 조성물 및 이의 사용 방법
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
EP4304725A1 (en) 2021-03-09 2024-01-17 CDR-Life AG Rabbit-derived antigen binding protein nucleic acid libraries
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
AU2022318257A1 (en) 2021-07-27 2024-02-08 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding ct45
CN115724988B (zh) * 2021-08-26 2023-11-17 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子
TW202332765A (zh) 2021-09-20 2023-08-16 美商英麥提克斯股份有限公司 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡
US20230190806A1 (en) 2021-10-06 2023-06-22 Immatics Biotechnologies Gmbh Methods of treating metastatic lesions and compositions thereof
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
KR20240116828A (ko) * 2021-12-14 2024-07-30 씨디알-라이프 아게 이중 mhc-표적화 t 세포 관여자
KR20240149435A (ko) 2022-02-20 2024-10-14 이뮤노코어 리미티드 Hiv 특이적 결합 분자
JP2025515603A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法
JP2025516189A (ja) 2022-04-28 2025-05-27 イマティクス ユーエス，アイエヌシー． 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
US20250354995A1 (en) * 2022-04-29 2025-11-20 Immatics Biotechnologies Gmbh Mammalian display platform for multispecific antigen binding proteins
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
EP4569324A1 (en) 2022-08-08 2025-06-18 Immatics Biotechnologies GmbH Guided positional scanning method
KR20250067130A (ko) 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
US12195534B2 (en) 2023-01-06 2025-01-14 Immunocore Limited Binding molecules
US12134647B2 (en) 2023-01-06 2024-11-05 Immunocore Limited Binding molecules
WO2025008513A1 (en) 2023-07-05 2025-01-09 Immatics Biotechnologies Gmbh A method of identifying mhc-binding proteins and interacting peptides in a sample
TW202506719A (zh) 2023-07-27 2025-02-16 德商艾瑪提克生物技術有限公司 針對mageb2之抗原結合蛋白
WO2025085855A2 (en) * 2023-10-20 2025-04-24 BioNTech SE Multispecific t cell engagers compositions and methods of use thereof
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2025094054A1 (en) * 2023-11-01 2025-05-08 Immunocore Limited Method for purifying small multi-domain proteins
GB202320012D0 (en) * 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026025031A1 (en) 2024-07-26 2026-01-29 Modernatx, Inc. Mrna encoding mageb2 tcer molecule
WO2026078231A1 (en) 2024-10-11 2026-04-16 T-Therapeutics Limited Soluble non-aggregating immune ligand
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100174053A1 (en) * 2005-04-15 2010-07-08 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2258719A1 (en) * 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20140242079A1 (en) * 2013-02-26 2014-08-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2014159940A1 (en) * 2013-03-14 2014-10-02 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
US20160208019A1 (en) * 2014-11-20 2016-07-21 Hoffmann-La Roche Inc. T cell activating bispecific antigen binding molecules
WO2016184592A1 (en) * 2015-05-19 2016-11-24 Klinikum Rechts Der Isar Der Tu München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
WO2017070608A1 (en) * 2015-10-23 2017-04-27 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
CN106831996A (zh) * 2017-03-31 2017-06-13 北京智仁美博生物科技有限公司 新型双特异性抗体及其用途
WO2017109496A1 (en) * 2015-12-22 2017-06-29 Immunocore Limited T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
PT1231268E (pt) 1994-01-31 2005-11-30 Univ Boston Bancos de anticorpos policlonais
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
DK1438400T3 (da) 2001-10-01 2009-10-05 Dyax Corp Flerkædede eukaryote display-vektorer og anvendelser deraf
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
NZ561338A (en) 2005-04-01 2010-04-30 Immunocore Ltd High affinity HIV T cell receptors
EP3479844B1 (en) 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
PL2002003T3 (pl) 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
US20110045007A1 (en) 2007-05-31 2011-02-24 Genmab A/S Fusion or linked proteins with extended half life
CA2711806A1 (en) 2008-01-11 2009-07-16 Morphosys Ag Display vectors and methods and uses thereof
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
CA2777053A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
CN102958942A (zh) 2009-12-29 2013-03-06 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
WO2011085178A1 (en) 2010-01-11 2011-07-14 Trustees Of Dartmouth College Monomeric bi-specific fusion protein
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
RS67768B1 (sr) 2010-11-30 2026-03-31 Chugai Pharmaceutical Co Ltd Terapijski agens koji indukuje citotoksičnost
SG193023A1 (en) 2011-02-11 2013-10-30 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
JP2015537043A (ja) 2012-11-30 2015-12-24 ロシュ グリクアート アーゲー 多機能タンパク質を含むがん細胞標的化ｍｈｃクラスｉを用いた循環性ウイルス特異的細胞傷害性ｔ細胞によるがん細胞の除去
CA2896359A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
HRP20250551T1 (hr) 2013-11-27 2025-06-20 Zymeworks Bc Inc. Bispecifični antigen-vezujući konstrukti koji ciljaju her2
UA129760C2 (uk) 2013-12-17 2025-07-30 Дженентек, Інк. Анти-cd3 антитіло та спосіб його застосування
TR201907352T4 (tr) 2014-03-25 2019-06-21 Merial Inc Atenüe edi̇lmi̇ş histophilus somni i̇çeren i̇mmünoloji̇k bi̇leşi̇mler
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201504502D0 (en) 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
US10744157B2 (en) 2015-03-26 2020-08-18 The Trustees Of Dartmouth College Anti-MICA antigen binding fragments, fusion molecules, cells which express and methods of using
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
US10130693B2 (en) 2015-08-28 2018-11-20 Immatics Biotechnologies Gmbh Peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
WO2017059900A1 (en) 2015-10-07 2017-04-13 Biontech Cell & Gene Therapies Gmbh Antigen receptors and uses thereof
WO2017060201A1 (en) 2015-10-09 2017-04-13 Immatics Biotechnologies Gmbh Anti-wt1/hla-specific antibodies
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
US11034767B2 (en) 2016-04-15 2021-06-15 Trustees Of Dartmouth College High affinity B7-H6 antibodies and antibody fragments
EP3472208B9 (en) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH T cell receptors and uses thereof
EP3475938B1 (en) 2016-06-27 2020-12-23 The Procter and Gamble Company Apparatus and method for assessing tooth-sensitivity treatment by oral-care product
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018026018A1 (ja) 2016-08-05 2018-02-08 国立大学法人東北大学 Ｔ細胞受容体の認識機構を用いたがん又は感染症の治療及び診断
US11453726B2 (en) 2016-09-15 2022-09-27 Quadrucept Bio Limited Multimers, tetramers and octamers
CN111094333A (zh) 2017-06-01 2020-05-01 斯图加特大学 异源二聚化的Ig结构域
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
CN109468278A (zh) 2017-09-08 2019-03-15 科济生物医药（上海）有限公司 基因工程化的t细胞及应用
JPWO2019151392A1 (ja) 2018-01-31 2021-02-04 国立大学法人東北大学 抗原特異的ｍｈｃ発現調節法
MX2020012124A (es) 2018-05-14 2021-04-19 Immunocore Ltd Polipeptidos de unión bifuncional.
EA202091977A1 (ru) 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
US20220275043A1 (en) 2018-07-17 2022-09-01 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
WO2020057610A1 (en) 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific anti-ctla-4/pd-1 polypeptide complexes
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
MX2022000667A (es) 2019-07-15 2022-07-21 Neogene Therapeutics B V Metodo para aislar genes tcr.
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) * 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
EP4025598A1 (en) 2019-09-06 2022-07-13 Eli Lilly and Company Proteins comprising t-cell receptor constant domains
US20220396635A1 (en) 2019-09-25 2022-12-15 Universität Stuttgart Trivalent binding molecules
EP4034570A4 (en) 2019-09-27 2023-10-25 Agenus Inc. HETERODIMERIC PROTEINS
AU2020384374A1 (en) 2019-11-15 2022-06-09 Seattle Project Corp. Antigen-binding proteins targeting shared neoantigens
EP4061827A1 (en) 2019-11-18 2022-09-28 BioNTech SE Prame tcr receptors and uses thereof
EP4077370A4 (en) 2019-12-17 2024-02-28 The Johns Hopkins University MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE
CN110964122B (zh) 2019-12-24 2022-04-15 南京北恒生物科技有限公司 T细胞受体融合蛋白及其用途
JP2023518049A (ja) 2020-03-16 2023-04-27 ユニバーシティ オブ サザン カリフォルニア 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体
US20230130925A1 (en) 2020-03-16 2023-04-27 University Of Southern California Methods to prevent, ameliorate and treat complications from viral infections
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
AU2021289612A1 (en) 2020-06-10 2023-01-19 The University Of Melbourne HIV-1 antibodies
EP4188416A4 (en) 2020-07-27 2024-08-21 Arizona Board of Regents on behalf of the University of Arizona MULTIFUNCTIONAL IMMUNOGLOBULIN-FOLDED POLYPEPTIDES FROM SUBSTITUTION TRANSLATIONAL INITIATION AND TERMINATION
US20230374140A1 (en) 2020-10-09 2023-11-23 Memorial Sloan Kettering Cancer Center Compositions targeting ndc80/mhc complexes and uses thereof
WO2022083668A1 (en) 2020-10-21 2022-04-28 Nanjing Legend Biotech Co., Ltd. Use of a chimeric co-stimulatory receptor for cell therapy
AU2021408160A1 (en) 2020-12-21 2023-06-29 Zymeworks Bc Inc. Stabilized tcr constructs and methods of use
AU2022224066A1 (en) 2021-02-19 2023-09-07 Angeles Therapeutics, Inc. Single-chain and multi-chain synthetic antigen receptors for diverse immune cells

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100174053A1 (en) * 2005-04-15 2010-07-08 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2258719A1 (en) * 2009-05-19 2010-12-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Multiple target T cell receptor
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20140242079A1 (en) * 2013-02-26 2014-08-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
WO2014159940A1 (en) * 2013-03-14 2014-10-02 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
US20160208019A1 (en) * 2014-11-20 2016-07-21 Hoffmann-La Roche Inc. T cell activating bispecific antigen binding molecules
WO2016184592A1 (en) * 2015-05-19 2016-11-24 Klinikum Rechts Der Isar Der Tu München T cell receptor with specificity for myeloperoxidase peptide and uses thereof
WO2017070608A1 (en) * 2015-10-23 2017-04-27 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017109496A1 (en) * 2015-12-22 2017-06-29 Immunocore Limited T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
CN106831996A (zh) * 2017-03-31 2017-06-13 北京智仁美博生物科技有限公司 新型双特异性抗体及其用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C.RADER: "DARTs take aim at BiTEs" *
CARTER: "Bispecific human IgG by design" *
LIQIN LIU ET AL: "MGD011,A CD19*CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Cirulating Half-life for the Treatment of B-Cell Malignancies" *
REITER ET AL: "Stablization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions" *
李芳谷等: "抗原特异性细胞毒性T细胞在病毒感染性疾病中的作用" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途

Also Published As

Publication number Publication date
HRP20211744T1 (hr) 2022-02-04
CO2020001491A2 (es) 2020-02-28
PL3652215T3 (pl) 2021-08-02
KR20200026994A (ko) 2020-03-11
AU2018298881B2 (en) 2025-04-17
EP3652215B1 (en) 2021-02-17
SI3428194T1 (sl) 2021-12-31
JP2024023385A (ja) 2024-02-21
PE20200615A1 (es) 2020-03-11
EP3985029A1 (en) 2022-04-20
US20250361300A1 (en) 2025-11-27
JP6784724B2 (ja) 2020-11-11
TWI762677B (zh) 2022-05-01
KR102833184B1 (ko) 2025-07-10
PL3428194T3 (pl) 2022-01-17
CY1124091T1 (el) 2022-05-27
US20190016803A1 (en) 2019-01-17
WO2019012141A1 (en) 2019-01-17
CR20200013A (es) 2020-03-11
US20230348598A1 (en) 2023-11-02
CR20200014A (es) 2020-06-11
KR20200026995A (ko) 2020-03-11
AU2018298884A1 (en) 2020-02-27
DK3428194T3 (da) 2021-11-15
MA46299B1 (fr) 2021-09-30
US11905328B2 (en) 2024-02-20
EP3428194A1 (en) 2019-01-16
TW202246330A (zh) 2022-12-01
US20190016802A1 (en) 2019-01-17
EP3652215A1 (en) 2020-05-20
DK3652215T3 (da) 2021-05-25
MD3428194T2 (ro) 2022-02-28
SG11202000027WA (en) 2020-02-27
AU2018298881A1 (en) 2020-01-16
EP3428194B1 (en) 2021-08-18
MA46299A (fr) 2019-07-31
JP2019023184A (ja) 2019-02-14
SI3652215T1 (sl) 2021-08-31
ES2898210T3 (es) 2022-03-04
BR112020000762A2 (pt) 2020-07-21
RS62544B1 (sr) 2021-12-31
MX2020011744A (es) 2021-01-08
CA3069610A1 (en) 2019-01-17
HUE057110T2 (hu) 2022-04-28
JP2020530762A (ja) 2020-10-29
CO2020001029A2 (es) 2020-02-18
PT3428194T (pt) 2021-11-18
CY1124835T1 (el) 2022-11-25
MD3652215T2 (ro) 2021-06-30
RS61817B1 (sr) 2021-06-30
CN110914308A (zh) 2020-03-24
LT3428194T (lt) 2021-12-10
HUE054568T2 (hu) 2021-09-28
US20220195044A1 (en) 2022-06-23
US20190016801A1 (en) 2019-01-17
US20220185888A1 (en) 2022-06-16
US20190016804A1 (en) 2019-01-17
PE20200614A1 (es) 2020-03-11
CA3069842A1 (en) 2019-01-17
ZA202000842B (en) 2022-06-29
PT3652215T (pt) 2021-05-18
ES2871146T3 (es) 2021-10-28
TWI817302B (zh) 2023-10-01
JP2023103451A (ja) 2023-07-26
SG11202000025SA (en) 2020-02-27
WO2019012138A1 (en) 2019-01-17
LT3652215T (lt) 2021-05-25
TW201908340A (zh) 2019-03-01
BR112020000769A2 (pt) 2020-07-21

Similar Documents

Publication Publication Date Title
US20230348598A1 (en) Improved dual specificity polypeptide molecule
HK40071054A (en) Improved dual specificity polypeptide molecule
JP2021019626A (ja) 改善された二重特異性ポリペプチド分子
HK40003407B (en) Improved dual specificity polypeptide molecule
HK40003407A (en) Improved dual specificity polypeptide molecule
EA043129B1 (ru) Усовершенствованная молекула полипептида с двойной специфичностью
EA043319B1 (ru) Усовершенствованная молекула полипептида с двойной специфичностью
HK40029654B (en) Improved dual specificity polypeptide molecule
HK40029654A (en) Improved dual specificity polypeptide molecule

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination